-
Annals of the Royal College of Surgeons... Apr 2020Parietal cell/oncocytic gastric carcinomas are very rare and various aspects of this group remain unclear. The human epithelial growth factor receptor 2 (HER2) status of...
INTRODUCTION
Parietal cell/oncocytic gastric carcinomas are very rare and various aspects of this group remain unclear. The human epithelial growth factor receptor 2 (HER2) status of these tumours is largely unknown.
METHODS
We performed a systematic electronic search of the literature and clinicopathological presentation of two cases including first-time complete assessment of HER2 status. Thirty-two patients with a mean age of 64.3 years, 87.5% of whom were male, were included in this review.
FINDINGS
Half of the cases were recorded in Asia. Median follow-up was 24 months. There was no predominant site of development, while underlying histological abnormalities were present in 25%. At initial presentation, lymph node involvement was evident in 46.6% while distant metastatic disease was present in 9.3%. Presentation at stage I occurred in 55.6%. Potentially curative surgical/interventional treatment was intended in 90.6%. Recurrence occurred in 6.6%, while death was recorded in 19.2%, with cancer-related deaths reaching 11.5%. The one- and three-year survival rates were 84.2% and 79%, respectively. Our two cases displayed negative HER2 expression.
CONCLUSIONS
This systematic review demonstrates that this group of malignancies is very rare but possibly underdiagnosed. The disease commonly presents at early stage, mainly affecting middle-aged men. The prognosis is generally favourable even in cases of advanced disease. The HER2 expression and its correlation with the outcomes need to be further explored.
Topics: Aged, 80 and over; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gastrectomy; Greece; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Parietal Cells, Gastric; Receptor, ErbB-2; Sex Factors; Stomach Neoplasms; Survival Rate
PubMed: 31928359
DOI: 10.1308/rcsann.2019.0183